logo
OCD's Origins Might Not Lie in The Brain Like We Thought

OCD's Origins Might Not Lie in The Brain Like We Thought

Yahoo08-07-2025
Obsessive-compulsive disorder (OCD) affects up to 3 percent of people worldwide and remains one of the most challenging mental health conditions to treat effectively.
That makes any fresh insight into OCD's root causes especially valuable – like a new study pointing to a surprising suspect: the bacteria living in our gut.
The research from China explored how the gut microbiota – the complex community of bacteria that live in the digestive system – may influence whether a person develops OCD, and identified six types of bacteria that appear to be linked with the condition.
A steady stream of studies has shown close connections between the brain and the gut, but this is the first to provide compelling evidence that gut bacteria may actually help cause it. The researchers used genetic data to strengthen the case for causation.
Related:
"Previous studies have indicated a potential link between the gut microbiota and OCD," write the researchers from Chongqing Medical University in their published paper. "However, the exact causal relationship remains uncertain."
"Our analysis suggested that specific gut microbiota might have a causal relationship with OCD, revealing potential intervention strategies for the prevention and treatment of this disorder."
To explore this link, the researchers used a genetic approach known as Mendelian randomization, which allows scientists to infer causality by analyzing genetic variants that influence both OCD and gut bacteria.
They assessed links between genetic data and gut bacteria in a sample of 18,340 people, and the links between genetic data and OCD in a separate sample of 199,169 people.
Although these were two discrete sets of data, the study used Mendelian randomization to essentially bridge the gap and connect gut bacteria patterns with OCD.
Because our genes are fixed at birth and not shaped by environment or lifestyle, this method helps strengthen the case that gut bacteria might directly contribute to OCD, rather than just being an effect of it.
However, more data and more controlled experiments will be needed to confirm a causal link.
Three types of bacteria appeared to be protective against OCD: Proteobacteria, Ruminococcaceae, and Bilophila. Another three seemed to increase the risk of OCD: Bacillales, Eubacterium, and Lachnospiraceae UCG001.
Interestingly, many of these bacteria have been linked with the brain before. For example, previous studies have found a connection between low levels of Ruminococcaceae species and depression. These findings expand what we already know about the gut-brain axis and how one can affect the other.
"Future research should employ longitudinal designs and diverse populations to validate and expand upon these findings, as well as a more in-depth classification of microbes and their metabolic products, to further understand the role of gut microbiota in OCD," write the researchers.
Down the line – and it's still a way off – we may have a new way to treat or prevent OCD, by controlling gut bacteria mixtures. For people living with the condition – and the families, friends, and clinicians who support them – this could eventually offer new hope.
"Despite the utilization of cognitive behavioral therapy and selective serotonin reuptake inhibitors in OCD treatment, a notable 25–40 percent of patients experience suboptimal or no response to these interventions," write the researchers.
"Moreover, the personal and societal toll of OCD is substantial."
The research has been published in the Journal of Affective Disorders.
The News Cycle Is a Stress Monster. But There's a Healthy Way to Stay Informed.
Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's
Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

OceanX Education Welcomes Science Engagement Leader Prof. Tit Meng Lim as APAC Regional Executive Director
OceanX Education Welcomes Science Engagement Leader Prof. Tit Meng Lim as APAC Regional Executive Director

Yahoo

time30 minutes ago

  • Yahoo

OceanX Education Welcomes Science Engagement Leader Prof. Tit Meng Lim as APAC Regional Executive Director

Renowned science educator and regional champion of STEM to lead OceanX Education's expansion and mission across Asia SINGAPORE, July 16, 2025 /PRNewswire/ -- OceanX Education is proud to announce the upcoming appointment of Professor Tit Meng Lim as its new APAC Regional Executive Director. Based in Singapore, Prof. Lim will lead the organization's growth and outreach efforts across Asia, guiding strategic vision, regional partnerships, and organizational development at a pivotal time for ocean literacy and environmental engagement. A household name in science education and public engagement, Prof. Lim brings more than 30 years of leadership experience spanning academia, government-linked institutions, and international science networks. He most recently served as Chief Executive of the Science Centre Singapore, where he oversaw national efforts to promote STEM innovation and led the transformation of science learning into vibrant, community-driven experiences. Prof. Lim also held leadership roles at the National University of Singapore for over two decades, including Vice Dean of the Faculty of Science, where he was instrumental in shaping interdisciplinary science curricula and advancing life sciences education. His influence extends beyond Singapore through board leadership positions with organizations such as the Asia Pacific Network of Science & Technology Centres and the Association of Science-Technology Centres (ASTC). "Tit Meng is a visionary," said Mark Dalio, Founder and Executive Chairman, OceanX Education. "His ability to bridge science, education, public engagement, and cross-cultural collaboration is unmatched. We're excited to work with him to grow OceanX Education's impact in Asia and build a dynamic, inclusive future for ocean learning." In his role as APAC Regional Executive Director, Prof. Lim will spearhead efforts to scale OceanX Education's footprint in the region, from establishing new programs that blend science, education, immersive storytelling, and public programming, to building institutional partnerships and long-term funding strategies. He will also oversee operations, organizational planning, and the expansion of OceanX Education's regional team. "OceanX Education stands at the crossroads of science, media, and mission-driven innovation," said Prof. Lim. "To be part of building a movement that brings the ocean to life for learners across the region is deeply meaningful. I'm honored to help lead this next chapter." This appointment marks a significant milestone in OceanX Education's global strategy, reinforcing its presence in Asia and commitment to developing the next wave of ocean leaders. For more information about OceanX's ongoing work, please visit the OceanX website. For media inquiries regarding OceanX, please contact Karuna Tuli at About OceanX OceanX is a nonprofit working to unlock the ocean's sustainable potential. Through a dual focus on science and education, we're building a new paradigm where humanity and the ocean mutually thrive. Our approach is fueled by exploration, leveraging advanced research, multimedia educational programs, cross-sector partnerships, and advanced technology to help transform how people understand and value the ocean. Our work strives to fortify biodiversity and increase the sustainable use of ocean resources to help ensure the ocean remains a foundation for human wellbeing and potential. OceanX is a nonprofit operating program of Dalio Philanthropies. For more information, visit and follow OceanX on Facebook, Instagram, X (formerly Twitter), TikTok, LinkedIn, and YouTube. View original content to download multimedia: SOURCE OceanX Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO
ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

Yahoo

timean hour ago

  • Yahoo

ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 15, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included in the PADO-RSV priority list. Ziresovir, developed by Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimization priority list. Filling a Global Gap: Ziresovir Leads RSV Antiviral Development RSV is the leading pathogen of lower respiratory tract infections (LRTIs) in infants and young children globally, causing approximately 33 million cases of LRTIs, 3.6 million hospitalizations, and 101,400 deaths annually, with 97% of deaths occurring in low- and middle-income countries (LMICs). Despite the severe threat, current specific treatment options for RSV are extremely limited, and there is a clinical urgent need for safe, effective, and child-appropriate innovative drugs. The "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV)" project initiated by WHO/GAP-f aims to systematically review the global R&D pipeline, clarify R&D priorities, and promote the development and accessibility of RSV prevention and treatment tools more suitable for the paediatric population. With its clear clinical value, child-friendly design, and good safety profile, ziresovir becomes the only product in the antiviral drug category selected for the PADO-RSV priority list, demonstrating its huge potential in the paediatric RSV treatment globally. WHO pointed out in the report that ziresovir's research results are of great significance to the global RSV treatment field and recommended conducting diverse clinical studies in broader populations to further verify its applicability and effectiveness. ArkBio will actively respond to WHO's advice with a plan to expand ziresovir's clinical development in other countries and regions. By collaborating with international scientific institutions and public health organizations, ArkBio aims to rapidly advance the drug's global registration and accessibility. Simultaneously, ArkBio is deeply aware of the importance of global public health, particularly concerned about the challenges faced by low- and middle-income countries. The company will formulate drug accessibility plans specifically for these countries to ensure ziresovir can be supplied at reasonable prices globally wherever it is needed, contributing to the prevention and treatment of RSV infection. "ArkBio has a mission to 'help patients inspire and thrive'", Dr. Jim Wu, CEO of ArkBio, stated. "The inclusion of ziresovir in the WHO PADO-RSV priority list is not only an affirmation of the years of effort by ArkBio scientists, but also an inspiration for our corporate mission. The recognition of ziresovir would allow us to expedite its global development and realize the potential on the global stage. We will ensure the innovation can not only benefit patients in China but the very needed patients worldwide. This is not just our goal but our social responsibility. ArkBio will strive to contribute more to address global public health issues." About GAP-f GAP-f stands for the Global Accelerator for Paediatric Formulations Network. Hosted by WHO, it operates throughout the drug development lifecycle to accelerate the research, development, and dissemination of optimized pediatric formulations. Identifying priorities is the first step toward a targeted R&D approach. Establishing a priority list of the most urgently needed pediatric formulations is crucial, as it helps focus the efforts and resources of researchers and suppliers on specific dosage forms and formulations that address children's most critical needs. About PADO PADO stands for Paediatric Drug Optimization. It is a WHO's legally binding international priority (based on WHA69.20 resolution) that accelerates the development of high-demand pediatric drugs by building consensus among regulators, funders, and manufacturers. It aims to identify priority products for R&D and define their ideal characteristics. It has been successfully implemented in areas including human immunodeficiency virus (HIV), hepatitis C, tuberculosis, COVID-19, antibiotics, neglected tropical diseases, and childhood cancers. These initiatives demonstrate that, against the backdrop of a fragmented and small pediatric drug market, such efforts hold potential and deliver tangible impacts in accelerating access to optimized formulations. About Ziresovir Ziresovir is a novel small-molecule RSV fusion (F) protein inhibitor. It binds to the pre-F protein conformation of the virus and prevents viral entry into human cells. Ziresovir can also suppress RSV viral transmission by blocking cell-to-cell fusion through the formation of "syncytia", a characteristic event of RSV infection of host cells. It is the first oral anti-RSV drug that has completed a phase 3 pivotal clinical study with positive results. The phase 3 results have been published in The New England Journal of Medicine and The Lancet Child & Adolescent Health. Ziresovir has received Breakthrough Therapy designation by the National Medical Products Administration (NMPA) of China. About ArkBio ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and Azstarys (AK0901), an FDA-approved ADHD therapeutic drug. ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions. For more information, please visit: Inquiries: IR@ View original content to download multimedia: SOURCE Arkbio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact
AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact

Yahoo

time2 hours ago

  • Yahoo

AbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact

- 880 AbbVie employees across 7 markets volunteered over 3,000 hours to support vulnerable groups.- Over 650 individuals benefited from 24 volunteer initiatives, delivered in partnership with 17 community organisations across the region. SINGAPORE, July 16, 2025 /PRNewswire/ -- AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation's annual global volunteering programme, held in June and July. This unites our employees around the world with a single purpose to serve our local communities. 880 employees across Singapore, Malaysia, Thailand, the Philippines, India, Taiwan region, and South Korea came together to engage in services tailored to the needs of their local communities through volunteer initiatives. Projects focused on supporting vulnerable groups, children, seniors, and individuals with health and social vulnerabilities. "Our people power the change we want to see in the world. Through Week of Possibilities, we're proud to stand alongside our partners across Asia to support the communities we live and work in, especially those who are often overlooked. Whether it's helping children, seniors, people with disabilities, or protecting our environment, every action brings us closer to a more equitable, healthier future," said Peggy Wu, Vice President, Asia, AbbVie. In Thailand, employees focused on supporting students in a rural community with limited resources by rebuilding unsafe classrooms, providing lunches, and donating essentials. In the Philippines, volunteers contributed to food rescue efforts, preparing meals for communities with unmet needs and hosting a special Kasama Ka programme to raise awareness around food security and sustainability. The India team led a month-long series of engagements: organising a sports day for children experiencing homelessness in Mumbai, visiting a senior home for musical games and companionship, conducting art-based environmental workshops with children from low-income communities in Bangalore, and running a personal hygiene session at a children's home in Delhi. In Taiwan region and Malaysia, inclusive events such as stage performances, craft-making, and cycling activities empowered individuals with disabilities through confidence-building experiences. In Korea, employees supported people with disabilities through community outings, pop art portraits, and eco-friendly installations at care facilities. In Singapore, employees fostered social connections with seniors and vulnerable individuals through creative activities and heritage tours, while also supporting environmental sustainability through waterways clean-ups. "We are deeply impressed by the passion and dedication of AbbVie volunteers, who actively participated and joyfully accompanied the disabled. This companionship brings not only encouragement but also respect and acceptance. Every time the volunteers cheer for the disabled, they help our foundation in promoting a more friendly treatment for people with disabilities," said Li Shu Yu, staff member of the Eden Social Welfare Foundation, Taiwan. Together, the WOP initiatives in Asia spanned healthcare, education, elderly support, environmental protection, and disability inclusion, reflecting the diverse needs of communities and the breadth of AbbVie's commitment. At the heart of every activity was a shared belief that health equity starts with local action and that everyone has equal access to the opportunity to thrive. Claire Chin, Area Head, Regulatory Affairs, AbbVie, shared, "June has always been my favourite month of the year at AbbVie. This year's theme for AbbVie's week of possibilities is advancing health equity. A lot of people might think of health equity as hospital visits and other charitable events. But in developed countries like Singapore, we tend to take our clean environment for granted. Before we consider advanced technologies and treatment options to support health, we have to first fulfil the basic human needs of hygiene, good health, and a good environment. To me, that's where we can start to work towards creating a healthy living environment for each of us." Launched in 2014, AbbVie's Week of Possibilities has grown into a cornerstone of the company's global culture, engaging employees in voluntary actions and an annual celebration of giving back. Powered in part by the AbbVie Foundation, the initiative rallies employees worldwide to volunteer and make a meaningful impact in the communities where they live and work. You can view images of AbbVie's Week of Possibilities volunteer initiatives in Asia here. Learn more about AbbVie's Week of Possibilities at and AbbVie's ongoing commitment to local communities in its 2024 ESG Action Report. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.. About the AbbVie Foundation The AbbVie Foundation is a 501(c)(3) nonprofit working to drive transformative change in communities worldwide so that everyone can live their healthiest life. We are committed to advancing health equity through innovative, community-led partnerships and through our employee impact programs around the world. For more information, please visit View original content to download multimedia: SOURCE AbbVie Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store